Homology Modeling of Human Alpha-Glucosidase Catalytic Domains and SAR Study of Salacinol Derivatives

Shinya Nakamura, Kazunori Takahira, Genzoh Tanabe, Osamu Muraoka, Isao Nakanishi

Department of Pharmaceutical Sciences, Kinki University, Kinki, Japan.

DOI: 10.4236/ojmc.2012.23007                

Abstract

Maltase-glucoamylase (MGAM) and sucrase-isomaltase (SI) belong to human intestinal alpha-glucosidase and their N-terminal side catalytic domains are called NtMGAM and NtSI, and their C-terminal side catalytic domains are called CtMGAM and CtSI. As an antidiabetic, alpha-glucosidase inhibitor is required to bind to all of these domains to inhibit disaccharides hydrolysis. Salacinol and kotalanol isolated from Salacia reticulata are novel seed compounds for al-pha-glucosidase inhibitor. Even though the complex structures of NtMGAM or NtSI have been determined experimen-tally, those of CtMGAM and CtSI have not been revealed. Thus, homology modeling for CtMGAM and CtSI has been performed to predict the binding mode of salacinol and its derivatives for each domain. The binding affinities for these compounds were also calculated to explain the experimental structure-activity relationships (SARs). After a docking study of the derivatives to each catalytic domain, the MM/PBSA method has been applied to predict the binding affinities. The predicted binding affinities were almost consistent with the experimental SARs. The comparison of the complex structures and binding affinities provided insights for designing novel compounds, which inhibit all catalytic domains.

Keywords

Homology Modeling; Docking Study; MM/PBSA; Alpha-Glucosidase; Salacinol; Kotalanol

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	H. A. Ernst, L. L. Leggio, M. Willemo?s, G. Leonard, P. Blum and S. Larsen, “Structure of the Sulfolobus Solfataricus Alpha-Glucosidase: Implications for Domain Conservation and Substrate Recognition in GH31,” Journal of Molecular Biology , Vol. 358, No. 4, 2006, pp. 11061124. doi:10.1016/j.jmb.2006.02.056
[2]	G. M. Gray, B. C. Lally and K. A. Conklin, “Action of Intestinal Sucrase-Isomaltase and Its Free Monomers on an α-Limit Dextrin,” The Journal of Biological Chemistry, Vol. 254, No. 13, 1979, pp. 6038-6043.
[3]	J. L. Chiasson, R. G. Josse, R. Gomis, M. Hanefeld, A. Karasik and M. Laakso, “Acarbose for Prevention of Type 2 Diabetes Mellitus: The STOP-NIDDM randomised Trial,” Lancet, Vol. 359, No. 9323, 2002, pp. 2072-2077. doi:10.1016/S0140-6736(02)08905-5
[4]	B. G?ke, H. Fuder, G. Wieckhorst, U. Theiss, E. Stridde, T. Littke, P. Kleist, R. Arnold and P. W. Lücker, “Voglibose (AO-128) Is an Efficient α-Glucosidase Inhibitor and Mobilizes the Endogenous GLP-1 Reserve,” Digestion, Vol. 56, No. 6, 1995, pp. 493-501. doi:10.1159/000201282
[5]	R. J. Andrade, M. Lucena, J. L. Vega, M. Torres, F. J. Salmeron, V. Bellot, M. D. Garcia-Escano and P. Moreno, “Acarbose-Associated Hepatotoxicity,” Diabetes Care, Vol. 21, No. 11, 1998, pp. 2029-2030. doi:10.2337/diacare.21.11.2029
[6]	M. Yoshikawa, T. Murakami, K. Yashiro and H. Matsuda, “Kotalanol, a Potent α-Glucosidase Inhibitor with Thiosugar Sulfonium Sulfate Structure, from Antidiabetic Ayurvedic Medicine Salacia reticulata,” Chemical and Pharmaceutical Bulletin, Vol. 46, No. 8, 1998, pp. 13391340. doi:10.1248/cpb.46.1339
[7]	M. Yoshikawa, T. Murakami, H. Shimada, H. Matsuda, J. Yamahara, G. Tanabe and O. Muraoka, “Salacinol, Potent Antidiabetic Principle with Unique Thiosugar Sulfonium Sulfate Structure from the Ayurvedic Traditional Medicine Salacia reticulata in Sri Lanka and India,” Tetrahedron Letters, Vol. 38, No. 48, 1997, pp. 8367-8370. doi:10.1016/S0040-4039(97)10270-2
[8]	L. Sim, K. Jayakanthan, S. Mohan, R. Nasi, B. D. Johnston, B. M. Pinto and D. R. Rose, “New Glucosidase Inhibitors from an Ayurvedic Herbal Treatment for Type 2 Diabetes: Structures and Inhibition of Human Intestinal Maltase-Glucoamylase with Compounds from Salacia reticulata,” Biochemistry, Vol. 49, No. 3, 2010, pp. 443451. doi:10.1021/bi9016457
[9]	L. Sim, C. Willesma, S. Mohan, Y. H. Naim, B. M. Pinto and D. R. Rose, “Structural Basis for Substrate Selectivity in Human Maltase-Glucoamylase and Sucrase-Isomaltase N-Terminal Domains,” The Journal of Biological Chemistry, Vol. 285, No. 23, 2010, pp. 17763-17770. doi:10.1074/jbc.M109.078980
[10]	R. Eskandari, K. Jones, D. R. Rose and B. M. Pinto, “Probing the Active-Site Requirements of Human Intestinal N-Terminal Maltase Glucoamylase: The Effect of Replacing the Sulfate Moiety by A Methyl Ether in Ponkoranol, a Naturally Occurring α-Glucosidase Inhibitor,” Bioorganic & Medicinal Chemistry Letters, Vol. 20, No. 19, 2010, pp. 5686-5689. doi:10.1016/j.bmcl.2010.08.020
[11]	M. Yoshikawa, F. Xu, S. Nakamura, T. Wang, H. Matsuda, G. Tanabe and O. Muraoka, “Salaprionol and Ponkoranol with Thiosugar Sulfonium Sulfate Structure from Salacia prinoides and α-Glucosidase Inhibitory Activity of Ponkoranol and Kotalanol Desulfate,” Heterocycles, Vol. 75, No. 6, 2008, pp. 1397-1405. doi:10.3987/COM-07-11315
[12]	S. Nakamura, K. Takahira, G. Tanabe, T. Morikawa, M. Sakano, K. Ninomiya, M. Yoshikawa, O. Muraoka and I. Nakanishi, “Docking and SAR Studies of Salacinol Derivatives as α-Glucosidase Inhibitors,” Bioorganic & Medicinal Chemistry Letters, Vol. 20, No. 15, 2010, pp. 4420-4423. doi:10.1016/j.bmcl.2010.06.059
[13]	G. Tanabe, T. Otani, W. Cong, T. Minematsu, K. Ninomiya, M. Yoshikawa and O. Muraoka, “Biological Evaluation of 3’-O-Alkylated Analogs of Salacinol, the Role of Hydrophobic Alkyl Group At 3’ Position in the Side Chain on the α-Glucosidase Inhibitory Activity,” Bioorganic & Medicinal Chemistry Letters, Vol. 21, No. 10, 2011, pp. 3159-3162. doi:10.1016/j.bmcl.2011.02.109
[14]	N. Eswar, B. Webb, M. A. Marti-Renom, M. S. Madhusudhan, D. Eramian, M. Shen, U. Pieper and A. ?ali “Comparative Protein Structure Modeling Using MODELLER,” Current Protocols in Protein Science, 2007, pp. 2.9.1-2.9.31. doi:10.1002/0471140864.ps0209s50
[15]	J. Aqvist, C. Medina and J. E. Samuelsson, “New Method for Predicting Binding-Affinity in Computer-Aided Drug Design,” Protein Engineering Design and Selection, Vol. 7, No. 3, 1994, pp. 385-391. doi:10.1093/protein/7.3.385
[16]	P. A. Kollman, I. Massova, C. Reyes, B. Kuhn, S. Huo, L. Chong, M. Lee, T. Lee, Y. Duan, W. Wang, O. Donini, P. Cieplak, J. Srinivasan, D. A. Case and T. E. Cheatham III, “Calculating Structures and Free Energies of Complex Molecules: Combining Molecular Mechanics and Continuum Models,” Accounts of Chemical Research, Vol. 33. No. 12, 2000, pp. 889-897. doi:10.1021/ar000033j
[17]	B. L. Nichols, S. Avery, P. Sen, D. M. Swallow, D. Hahn and E. Sterchi, “The Maltase-Glucoamylase Gene: Common Ancestry to Sucrase-Isomaltase with Complementary Starch Digestion Activities,” Proceedings of the National Academy of Sciences, Vol. 100. No. 3, 2003, pp. 1432-1437. doi:10.1073/pnas.0237170100
[18]	S. R. Eddy, “Where Did the BLOSUM62 Alignment Score Matrix Come From?” Nature Biotechnology, Vol. 22, No. 8, 2004, pp. 1035-1036. doi:10.1038/nbt0804-1035
[19]	A. ?ali and T. L. Blundell, “Comparative Protein Modelling by Satisfaction of Spatial Restraints,” Journal of Molecular Biology, Vol. 234, No. 3, 1993, pp. 779-815. doi:10.1016/S1357-4310(95)91170-7
[20]	S. S. Sheik, P. Sundararajan, A. S. Z. Hussain and K. Sekar, “Ramachandran Plot on the Web,” Bioinformatics, Vol. 18, No. 11, 2002, pp. 1548-1549. doi:10.1093/bioinformatics/18.11.1548
[21]	R Lüthy, J. U. Bowie and D. Eisenberg, “Assessment of Protein Models with Three-Dimensional Profiles,” Nature, Vol. 356, No. 6364, 1992, pp. 83-85. doi:10.1038/356083a0
[22]	A. D. MacKerell Jr., D. Bashford, M. Bellott, R. L. Dunbrack Jr., J. D. Evanseck, M. J. Field, S. Fischer, J. Gao, H. Guo, S. Ha, D. Joseph-McCarthy, L. Kuchnir, K. Kuczera, F. T. K. Lau, C. Mattos, S. Michnick, T. Ngo, D. T. Nguyen, B. Prodhom, W. E. Reiher III, B. Roux, M. Schlenkrich, J. C. Smith, R. Stote, J. Straub, M. Watanabe, J. Wiórkiewicz-Kuczera, D. Yin and M. Karplus, “All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins,” The Journal of Physical Chemistry B, Vol.
[23]	MOE ver.2010, Chemical Computing Group Inc., Montreal. http://www.chemcomp.com/
[24]	B. R. Brooks, R. E. Bruccoleri, B. D. Olafson, D. J. States, S. Swaminathan and M. Karplus, “CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations,” Journal of Computational Chemistry, Vol. 4, No. 2, 1983, pp. 187-217. doi:10.1002/jcc.540040211
[25]	T. A. Halgren and R. B. Nachbar, “Merck Molecular Force Field. IV. Conformational Energies and Geometries for MMFF94,” Journal of Computational Chemistry, Vol. 17, No. 5-6, 1996, pp. 587-615. doi:10.1002/(SICI)1096-987X(199604)17:5/6<587::AID-JCC4>3.0.CO;2-Q
[26]	P. Labute, “The Generalized Born/Volume Integral Implicit Solvent Model: Estimation of the Free Energy of Hydration Using London Dispersion Instead of Atomic Surface Area,” Journal of Computational Chemistry, Vol. 29, No. 10, 2008, pp. 1693-1698. doi:10.1002/jcc.20933
[27]	L. Ren, X. Qin, X. Cao, L. Wang, F. Bai, G. Bai and Y. Shen, “Structural Insight into Substrate Specificity of Human Intestinal Maltase-Glucoamylase,” Protein Cell, Vol. 2, No. 10, 2011, pp. 827-836. doi:10.1007/s13238-011-1105-3
[28]	InsightII ver.2000, Accelrys Inc. San Diego, CA. http://accelrys.com/
[29]	J. P. Ryckaert, G. Ciccotti and H. J. C. Berendsen, “Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes,” Journal of Computational Physics, Vol. 23. No. 3, 1977, pp. 327-341. doi:10.1016/0021-9991(77)90098-5
[30]	M. K. Gilson, K. Sharp and B. Honig, “Calculating the Electrostatic Potential of Molecules in Solution: Method and Error Assessment,” Journal of Computational Chemistry, Vol. 9, No. 4, 1988, pp. 327-335. doi:10.1002/jcc.540090407
[31]	M. Sanner, A. J. Olson and J. C. Spehner, “Reduced Surface: An Efficient Way to Compute Molecular Surfaces,” Biopolymers, Vol. 38, No. 3, 1996, pp. 305-320. doi:10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.0.CO;2-Y
[32]	D. Sitkoff, K. A. Sharp and B. Honig, “Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models,” The Journal of Physical Chemistry, Vol. 98, No. 7, 1994, pp. 1978-1988. doi:10.1021/j100058a043
[33]	L. Ren, X. Cao, P. Geng, F. Bai and G. Bai, “Study of the Inhibition of Two Human Maltase-Glucoamylases Catalytic Domains by Different α-Glucosidase Inhibitors,” Carbohydrate Research, Vol. 346, No. 17, 2011, pp. 2688-2692. doi:10.1016/j.carres.2011.09.012
[34]	K. Jones, L. Sim, S. Mohan, J. Kumarasamy, H. Liu, S. Avery, H. Y. Naim, R. Quezada-Calvillo, B. L. Nichols, B. M. Pinto and D. R. Rose, “Mapping the Intestinal Alpha-Glucogenic Enzyme Specificities of Starch Digesting Maltase-Glucoamylase and Sucrase-Isomaltase,” Bioorganic & Medicinal Chemistry, Vol. 19, No. 13, 2011, pp. 3929-3934. doi:10.1016/j.bmc.2011.05.033
[35]	G. Tanabe, S. Nakamura, N. Tsutsui,G. Balakishan, W, Xie, S. Tsuchiya, J. Akaki, T. Morikawa, K. Ninomiya, I. Nakanishi, M. Yoshikawa and O. Muraoka, “In Silico Design, Synthesis and Evaluation of 3’-O-Benzylated Analogs of Salacinol, a Potent-Glucosidase Inhibitor from Ayurvedic Traditional Medicine ‘Salacia’,” Chemical Communications, 2012, in Press. doi:10.1039/c2cc34144a